Open AccessSomatrogon (Ngenla)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.292
Subject(s) - somatropin , growth hormone , growth hormone deficiency , medicine , pediatrics , family medicine , hormone
CADTH recommends that Ngenla should be reimbursed by public drug plans for the treatment of growth hormone deficiency if certain conditions are met.
Ngenla should only be covered to treat children who are at least 3 years of age, who did not reach puberty yet, and who are diagnosed with growth hormone deficiency.
Ngenla should only be reimbursed if prescribed by a pediatric endocrinologist and if it does not cost more than the least costly somatropin.